# Towards virtual laboratory for optimizing cardiac rhythm

> **NIH NIH R44** · CARDIOSOLV ABLATION TECHNOLOGIES, INC. · 2020 · $1,403,937

## Abstract

PROJECT SUMMARY
CardioSolv Ablation Technologies, Inc. has developed and aims to commercialize a simulation-based
approach for non-invasive prediction of the optimal targets of catheter ablation in patients with infarct-
related ventricular tachycardia. Successful completion of the commercialization will result in a major
paradigm shift in the clinical procedure of ventricular tachycardia ablation, where accurate prediction of
the optimal targets of ablation in each patient heart will be carried out by CardioSolv’s methodology
prior to the clinical procedure. Guided by these predictions, delivery of ablation will be swift and precise,
eradicating all infarct-related ventricular tachycardias with minimum lesion sizes. This will result in a
dramatic improvement in the efficacy of and tolerance for the therapy, as well as in reduction of post-
procedure complications.
The aim of this project is to complete a clinical trial to collect data in support of safety, efficacy, and
labeling claims, with the ultimate goal of regulatory clearance to market the device.

## Key facts

- **NIH application ID:** 9940751
- **Project number:** 5R44HL124901-05
- **Recipient organization:** CARDIOSOLV ABLATION TECHNOLOGIES, INC.
- **Principal Investigator:** Brock Michael Tice
- **Activity code:** R44 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $1,403,937
- **Award type:** 5
- **Project period:** 2014-08-01 → 2022-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9940751

## Citation

> US National Institutes of Health, RePORTER application 9940751, Towards virtual laboratory for optimizing cardiac rhythm (5R44HL124901-05). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/9940751. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*